Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis.
Respir Med
; 98(11): 1035-44, 2004 Nov.
Article
em En
| MEDLINE
| ID: mdl-15526803
ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary disease leading to death within a few years of diagnosis despite medical therapy. On the basis of methodologies of the Cochrane collaboration, this overview discusses the evidence for IPF therapy. Good-quality studies on oral corticosteroids, the most common medical therapy in use for IPF, are lacking. A few small studies have been carried out on the efficacy of many non-steroid immunosuppressive agents, and the results have been generally disappointing. The most extensively studied medical therapy, gamma interferon, showed a significant effect in a small randomized study, but its efficacy was not confirmed in a larger randomized-controlled trial. The long-awaited good news for patients affected by this deadly disease, and for their physicians, could come in the near future from large randomized-controlled trials with gamma interferon or other immunomodulatory agents.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fibrose Pulmonar
/
Corticosteroides
/
Imunossupressores
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Guideline
Limite:
Humans
Idioma:
En
Revista:
Respir Med
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Itália